文献速递主动脉疾病

基于目标动脉瘤概念的胸主动脉腔内修复术治疗广泛慢性B型夹层的长期 outcomes

Long-term outcomes of thoracic endovascular aortic repair using a target aneurysm-based approach for extensive chronic type B aortic dissection.
PubMed 文献 · J Vasc Surg · 2026-07-13

本研究回顾性分析了124例广泛慢性B型主动脉夹层患者,采用基于目标动脉瘤(TA)的治疗概念评估胸主动脉腔内修复术的长期结局。TA技术成功率和临床成功率分别为96.8%和73.9%,5年免于开放转换、主动脉相关死亡和TA相关再干预率分别为98.3%、91.5%和59.7%。TA临床成功与所有长期终点显著相关,支持TA框架的临床有效性。

要点

  • TA临床成功与开放转换、主动脉相关死亡及再干预的长期结局显著相关。
  • 基于TA概念的腔内修复可获得良好的形态学结果,84.0%患者动脉瘤缩小或稳定。
  • 早期影像学评估TA临床成功对预后判断具有重要意义。

核心结论

  • TA临床成功与cTBAD腔内修复术后长期结局强相关,支持TA治疗概念的有效性。

研究设计与样本

  • 回顾性分析2007年7月至2023年12月期间因广泛cTBAD接受初次腔内修复的患者,共124例,平均年龄62.9±11.6岁,男性占83.9%。

主要发现

  • TA技术成功率和CV技术成功率分别为96.8%和17.7%。
  • TA临床成功率和CV临床成功率(1个月)分别为73.9%和14.3%。
  • 中位随访60个月(IQR 29-106),5年免于OC、ARD和TA相关再干预率分别为98.3%、91.5%和59.7%。
  • TA水平形态学结果良好,84.0%患者动脉瘤缩小或直径稳定。

关键数值与推荐

  • TA定义为基于尺寸或生长标准需要治疗的动脉瘤段。
  • TA技术成功定义为术毕TA水平假腔灌注消失。
  • TA临床成功定义为术后1个月CTA显示TA持续隔绝。
  • CV成功要求完全隔绝假腔灌注。

临床怎么用

  • 采用TA-based框架评估cTBAD腔内修复的技术和临床成功,关注TA水平假腔灌注消失及持续隔绝。
  • 术后1个月CTA评估TA临床成功,有助于识别长期预后不良的高危患者。

局限性

  • 回顾性研究设计。
  • 单中心经验。
  • 样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Conventional (CV) aneurysm-based success definitions are often insufficient for evaluating endovascular repair for chronic type B aortic dissection (cTBAD). This study aimed to assess the clinical validity of a target aneurysm (TA)-based treatment concept. METHODS: We retrospectively analyzed patients who underwent initial endovascular repair for extensive cTBAD between July 2007 and December 2023. The TA was defined as the aneurysmal segment requiring treatment based on size or growth criteria. Technical and clinical success were defined using both TA-based and CV frameworks. TA technical success was defined as elimination of false lumen perfusion at the TA level at procedure completion, and TA clinical success as sustained exclusion of the TA on 1-month computed tomography angiography. CV success required complete exclusion of false lumen perfusion. The primary endpoint was morphologic outcome of the TA, including changes in aneurysm size. Secondary endpoints included open conversion (OC), aorta-related death (ARD), and TA-related reinterventions. RESULTS: A total of 124 patients (mean age, 62.9 ± 11.6 years; 83.9% male) were included. TA and CV technical success were achieved in 96.8% and 17.7%, respectively, whereas TA and CV clinical success at 1 month were observed in 73.9% and 14.3% of evaluable patients. During a median follow-up of 60 months (interquartile range, 29-106 months), freedom from OC, ARD, and TA-related reintervention at 5 years were 98.3%, 91.5%, and 59.7%, respectively. Morphologic outcomes at the TA level were favorable, with shrinkage or stable diameter observed in 84.0% of patients. Long-term outcomes differed significantly according to TA clinical success across all endpoints, including OC (P = .013), ARD (P = .013), and both overall and TA-related reintervention (both P < .001). TA shrinkage was more frequent in patients with TA clinical success than in those without (55.7% vs 25.8%; P = .013). CONCLUSIONS: TA clinical success was strongly associated with long-term outcomes after endovascular repair for cTBAD. These findings support the validity of the TA-based treatment concept and highlight the importance of early imaging-based assessment as a clinically meaningful framework for evaluating procedural success in cTBAD. Endovascular repair of extensive cTBAD guided by the TA-based treatment concept offers favorable clinical outcomes including avoidance of thoracoabdominal repair and ARD.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Shukuzawa K, Ohki T, Hara M, et al. Long-term outcomes of thoracic endovascular aortic repair using a target aneurysm-based approach for extensive chronic type B aortic dissection. J Vasc Surg. 2026. PMID: 42442641. doi:10.1016/j.jvs.2026.06.159

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。